Literature DB >> 7929306

Human kappa opiate receptor second extracellular loop elevates dynorphin's affinity for human mu/kappa chimeras.

J B Wang1, P S Johnson, J M Wu, W F Wang, G R Uhl.   

Abstract

To investigate roles of second extracellular loop sequences in peptide and nonpeptide ligand recognition by human opiate receptors, we have constructed a chimeric receptor in which this domain of the human mu opiate receptor has been replaced with that of the human kappa opiate receptor. The chimeric opiate receptor displays dramatically increased affinity for dynorphin peptides. Affinities for dynorphin A-(1-17), dynorphin A-(1-13), and alpha-neoendorphin increase by up to 250-fold when compared with the wild-type human mu opiate receptor. The chimera maintains recognition of the mu-selective ligands morphine and [D-Ala2,MePhe4,Gly-ol5]enkephalin and displays no significant changes in affinity for the kappa-selective small molecule ligand U50,488. The chimeric opiate receptor displays evidence for effective G-protein coupling; 100 nM dynorphin A-(1-17) is as effective as 100 nM morphine at inhibiting forskolin-stimulated adenyl cyclase activity through actions at the chimeric receptor. These data suggest that the putative second extracellular loop contributes substantially to the kappa receptor's selectivity in dynorphin ligand recognition.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929306

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Molecular modeling study of the differential ligand-receptor interaction at the mu, delta and kappa opioid receptors.

Authors:  M Filizola; M Carteni-Farina; J J Perez
Journal:  J Comput Aided Mol Des       Date:  1999-07       Impact factor: 3.686

Review 2.  Homology modeling of opioid receptor-ligand complexes using experimental constraints.

Authors:  Irina D Pogozheva; Magdalena J Przydzial; Henry I Mosberg
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 3.  Molecular recognition of opioid receptor ligands.

Authors:  Brian E Kane; Bengt Svensson; David M Ferguson
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

4.  Chemotype-selective modes of action of κ-opioid receptor agonists.

Authors:  Eyal Vardy; Philip D Mosier; Kevin J Frankowski; Huixian Wu; Vsevolod Katritch; Richard B Westkaemper; Jeffrey Aubé; Raymond C Stevens; Bryan L Roth
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

Review 5.  Mode matches and their locations in the hydrophobic free energy sequences of peptide ligands and their receptor eigenfunctions.

Authors:  A J Mandell; K A Selz; M F Shlesinger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

Review 6.  Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides.

Authors:  B L Kieffer
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

7.  Laminar distribution of the multiple opioid receptors in the human cerebral cortex.

Authors:  J M Hiller; L Q Fan
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

8.  The seventh transmembrane domains of the delta and kappa opioid receptors have different accessibility patterns and interhelical interactions.

Authors:  Wei Xu; Mercedes Campillo; Leonardo Pardo; J Kim de Riel; Lee-Yuan Liu-Chen
Journal:  Biochemistry       Date:  2005-12-13       Impact factor: 3.162

9.  Ligand/kappa-opioid receptor interactions: insights from the X-ray crystal structure.

Authors:  Karina Martinez-Mayorga; Kendall G Byler; Austin B Yongye; Marc A Giulianotti; Colette T Dooley; Richard A Houghten
Journal:  Eur J Med Chem       Date:  2013-05-30       Impact factor: 6.514

10.  Identification, structure-activity relationships and molecular modeling of potent triamine and piperazine opioid ligands.

Authors:  Austin B Yongye; Jon R Appel; Marc A Giulianotti; Colette T Dooley; Jose L Medina-Franco; Adel Nefzi; Richard A Houghten; Karina Martínez-Mayorga
Journal:  Bioorg Med Chem       Date:  2009-06-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.